樂普生物-B(02157.HK):與ASTRAZENECA就CMG901訂立的許可協議的最新進展
格隆匯4月15日丨樂普生物-B(02157.HK)發佈公吿,有關KYM Biosciences Inc.(“KYM”,一家由公司與康諾亞生物醫藥科技有限公司(“康諾亞”)成立的合營企業)與AstraZeneca AB(“AstraZeneca”,一家全球製藥公司)就開發及商業化CMG901(公司與康諾亞通過KYM共同開發的候選藥物)而訂立的全球獨家許可協議的最新情況。
2023年2月,KYM與AstraZeneca訂立許可協議,以開發及商業化CMG901。於簽署許可協議後及在就許可交易取得若干監管批准後,AstraZeneca於2023年2月獲授CMG901的研究、開發、註冊、生產及商業化的獨家全球許可,並須根據許可協議負責與其進一步開發及商業化相關的所有成本及活動。
截至本公吿日期,AstraZeneca已就CMG901治療晚期實體瘤開展了多項臨牀研究。一項在表達Claudin 18.2的晚期或轉移性胃及胃食管結合部腺癌受試者中比較CMG901單藥與研究者選擇的方案作為二線或二線以上治療的國際多中心III期研究已於2024年3月在藥物臨牀試驗登記與信息平台進行公示,首例受試者已於2024年4月11日完成首次給藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.